Lumos Pharma lumos-pharma.com


Public list: Smart Money VCs (6327) Pharma Startups (6570) Rare Diseases (230)

Lumos Pharma is focused on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. Lumos Pharma is led by an experienced management team with longstanding experience in the rare disease space. Lumos Pharma's lead compound is supported by the National Institutes of Health's Therapeutics for Rare and Neglected Diseases program.

Lumos Pharma is focused on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. Lumos Pharma is led by an experienced management team with longstanding experience in the rare disease space. Lu...Show all

Company (Alive / Active)

Phone: 512-215-2630

Fax:

4200 Marathon Blvd.
Suite 200
Austin, 78756
Texas, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Lumos Pharma $48M Apr 6, 2016

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Lumos Pharma Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 6 investors

Competitors

Company Status Description Investors

Audentes Therapeutics

San Francisco, California, United States
IPO / Went publicAudentes is a biotechnology company committed to the development and commercialization of treatments for people with serious, rare diseases through the application of AAV gene therapy technology. The company has three products in development, AT001 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT002 for the treatment of Pompe disease, and AT003 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).Login to see details

Patents

Title Application Date Patent Date Status
(Patent / Application)
Synthesis of cyclocreatine and analogs thereof Mar 11, 2016 Application
Cyclocreatine microsuspension Mar 09, 2016 Application
Synthesis of cyclocreatine and analogs thereof Sep 01, 2015 Application